Pharmaceutical Products Companies By Pb Ratio

Price To Book
Price To BookEfficiencyMarket RiskExp Return
1MRSN Mersana Therapeutics
261.43
 0.09 
 6.68 
 0.59 
2HURA TuHURA Biosciences
98.25
(0.13)
 7.99 
(1.01)
3DRUG Bright Minds Biosciences
52.14
 0.15 
 126.80 
 18.43 
4MBIO Mustang Bio
31.75
(0.11)
 6.21 
(0.70)
5DRRX Durect
25.0
(0.16)
 4.30 
(0.70)
6MNPR Monopar Therapeutics
20.27
 0.14 
 76.56 
 10.34 
7TLX Telix Pharmaceuticals Limited
19.0
(0.22)
 1.85 
(0.41)
8DYAI Dyadic International
12.92
 0.07 
 5.01 
 0.34 
9VCEL Vericel Corp Ord
10.98
 0.09 
 3.06 
 0.27 
10MDWD Mediwound
10.13
(0.04)
 3.13 
(0.11)
11VERA Vera Therapeutics
10.02
 0.09 
 3.81 
 0.35 
12MIRM Mirum Pharmaceuticals
9.04
 0.05 
 2.51 
 0.12 
13MDGL Madrigal Pharmaceuticals
8.9
 0.11 
 4.57 
 0.51 
14MREO Mereo BioPharma Group
7.66
(0.11)
 3.42 
(0.37)
15VCNX Vaccinex
7.34
(0.02)
 8.77 
(0.22)
16MLTX MoonLake Immunotherapeutics
6.44
 0.04 
 3.14 
 0.11 
17VKTX Viking Therapeutics
6.3
(0.04)
 5.15 
(0.22)
18MIRA MIRA Pharmaceuticals, Common
5.86
(0.04)
 7.62 
(0.33)
19MCRB Seres Therapeutics
5.81
(0.01)
 6.37 
(0.08)
20MGTX MeiraGTx Holdings PLC
4.75
 0.16 
 3.74 
 0.62 
The analysis above is based on a 90-day investment horizon and a default level of risk. Use the Portfolio Analyzer to fine-tune all your assumptions. Check your current assumptions here.
Price to Book (P/B) ratio is used to relate a company book value to its current market price. A high P/B ratio indicates that investors expect executives to generate more returns on their investments from a given set of assets. Book value is the accounting value of assets minus liabilities. Price to Book ratio is mostly used in financial services industries where assets and liabilities are typically represented by dollars. Although low Price to Book ratio generally implies that the firm is undervalued, it is often a good indicator that the company may be in financial or managerial distress and should be investigated more carefully.